{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:07:35Z","timestamp":1784128055769,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02884-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:41:27Z","timestamp":1784126487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longer vs. shorter all-oral bedaquiline-based regimens for drug-resistant tuberculosis: real-world evidence from a high-burden setting"],"prefix":"10.1007","author":[{"given":"Rashmi","family":"Ratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Awadh Singh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2884_CR1","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025. Geneva: WHO; 2025."},{"key":"2884_CR2","volume-title":"WHO consolidated guidelines on tuberculosis: Module 4 \u2013 treatment of drug-resistant tuberculosis (2022 update)","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4 \u2013 treatment of drug-resistant tuberculosis (2022 update). Geneva: WHO; 2022."},{"key":"2884_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1604544","volume":"376","author":"NS Shah","year":"2017","unstructured":"Shah NS, Auld SC, Brust JCM, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376:243\u201353.","journal-title":"N Engl J Med"},{"key":"2884_CR4","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1164\/rccm.201909-1819LE","volume":"201","author":"S Andres","year":"2020","unstructured":"Andres S, Merker M, Heyckendorf J, et al. Bedaquiline-resistant tuberculosis: dark clouds on the horizon. Am J Respir Crit Care Med. 2020;201:1564\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"2884_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","volume":"22","author":"R Banerjee","year":"2022","unstructured":"Banerjee R, Allen J, Westenhouse J, et al. Prevalence and risk factors for resistance to bedaquiline and linezolid in tuberculosis. Lancet Infect Dis. 2022;22:43\u201356.","journal-title":"Lancet Infect Dis"},{"key":"2884_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant, intolerant or non-responsive multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"key":"2884_CR7","first-page":"1616","volume":"67","author":"O Olayanju","year":"2018","unstructured":"Olayanju O, Limberis J, Esmail A, et al. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis. Clin Infect Dis. 2018;67:1616\u201320.","journal-title":"Clin Infect Dis"},{"key":"2884_CR8","doi-asserted-by":"publisher","first-page":"1901902","DOI":"10.1183\/13993003.01902-2019","volume":"55","author":"EA Kendall","year":"2020","unstructured":"Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9-month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Eur Respir J. 2020;55:1901902. https:\/\/doi.org\/10.1183\/13993003.01902-2019.","journal-title":"Eur Respir J"},{"key":"2884_CR9","doi-asserted-by":"publisher","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","volume":"55","author":"S Abidi","year":"2020","unstructured":"Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020;55:1901467.","journal-title":"Eur Respir J"},{"key":"2884_CR10","volume-title":"Guideline: nutritional care and support for patients with tuberculosis","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Guideline: nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013."},{"key":"2884_CR11","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2022."},{"key":"2884_CR12","volume-title":"National Tuberculosis Elimination Programme (NTEP): Guidelines for Programmatic Management of Drug-Resistant Tuberculosis (PMDT) in India","author":"TB Central","year":"2021","unstructured":"Central TB, Division. Ministry of Health and Family Welfare, Government of India. National Tuberculosis Elimination Programme (NTEP): Guidelines for Programmatic Management of Drug-Resistant Tuberculosis (PMDT) in India. New Delhi: MoHFW; 2021."},{"key":"2884_CR13","doi-asserted-by":"publisher","first-page":"1134938","DOI":"10.3389\/fpubh.2023.1134938","volume":"11","author":"JM Mijiti","year":"2023","unstructured":"Mijiti JM, Chuangyue P, Qian H, Weiguo G, Jihong T. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study. Front Public Health. 2023;11:1134938. https:\/\/doi.org\/10.3389\/fpubh.2023.1134938.","journal-title":"Front Public Health"},{"key":"2884_CR14","first-page":"114","volume":"24","author":"P Baghaei","year":"2025","unstructured":"Baghaei P, Campbell JR, Mahdavian A, Abtahian Z, Marjani M, Moniri A, et al. Traditional and short course treatment for multidrug-resistant tuberculosis: a comparative study in national referral centers. Tanaffos. 2025;24:114\u201327. PMID: 42027441.","journal-title":"Tanaffos"},{"key":"2884_CR15","doi-asserted-by":"publisher","first-page":"1645820","DOI":"10.3389\/fmed.2025.1645820","volume":"12","author":"A Karnan","year":"2025","unstructured":"Karnan A, Jadhav U, Ghewade B, Alone V. Comparing the longer regimen and the shorter regimen for multidrug-resistant pulmonary tuberculosis patients treated under the programmatic management of drug-resistant tuberculosis. Front Med (Lausanne). 2025;12:1645820. https:\/\/doi.org\/10.3389\/fmed.2025.1645820.","journal-title":"Front Med (Lausanne)"},{"key":"2884_CR16","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.3390\/ijerph18084121","volume":"18","author":"A Trubnikov","year":"2021","unstructured":"Trubnikov A, Hovhannesyan A, Akopyan K, Ciobanu A, Sadirova D, Kalandarova L, Parpieva N, Gadoev J. Effectiveness and safety of a shorter treatment regimen in a setting with a high burden of multidrug-resistant tuberculosis. Int J Environ Res Public Health. 2021;18:4121. https:\/\/doi.org\/10.3390\/ijerph18084121.","journal-title":"Int J Environ Res Public Health"},{"key":"2884_CR17","doi-asserted-by":"crossref","unstructured":"Soedarsono PA, Agustiyanto C, Rampengan VRC. Limited success and high attrition in the 9-month all-oral regimen for MDR-TB: evidence from a tertiary care setting in Indonesia. Indian J Tuberc. 2025.","DOI":"10.1016\/j.ijtb.2025.08.001"},{"key":"2884_CR18","doi-asserted-by":"publisher","first-page":"973713","DOI":"10.3389\/fphar.2022.973713","volume":"13","author":"A Wahid","year":"2022","unstructured":"Wahid A, Ghafoor A, Khan AW, Al-Worafi YM, Latif A, Shahwani NA, Atif M, Saleem F, Ahmad N. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol. 2022;13:973713. https:\/\/doi.org\/10.3389\/fphar.2022.973713.","journal-title":"Front Pharmacol"},{"key":"2884_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12879-024-09960-3","volume":"24","author":"Y Abraham","year":"2024","unstructured":"Abraham Y, Assefa DG, Hailemariam T, Gebrie D, Debela DT, Geleta ST, et al. Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a systematic review and network meta-analysis. BMC Infect Dis. 2024;24:1087. https:\/\/doi.org\/10.1186\/s12879-024-09960-3.","journal-title":"BMC Infect Dis"},{"key":"2884_CR20","doi-asserted-by":"publisher","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","volume":"55","author":"S Abidi","year":"2020","unstructured":"Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Tr\u00e9bucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Khan FA. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020;55:1901467. https:\/\/doi.org\/10.1183\/13993003.01467-2019.","journal-title":"Eur Respir J"},{"key":"2884_CR21","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.","journal-title":"Nat Rev Dis Primers"},{"key":"2884_CR22","first-page":"e000387","volume":"2","author":"K L\u00f6nnroth","year":"2017","unstructured":"L\u00f6nnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics. BMJ Glob Health. 2017;2:e000387.","journal-title":"BMJ Glob Health"},{"key":"2884_CR23","unstructured":"Clinical Trials Registry\u2013India (CTRI). BEAT-India study: evaluation of six-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine regimen for drug-resistant tuberculosis. National Institute of Research in Tuberculosis (NIRT), India. Available at: https:\/\/ctri.nic.in (Accessed 2026 May 3)."},{"key":"2884_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12:117\u201328. https:\/\/doi.org\/10.1016\/S2213-2600(23)00389-2.","journal-title":"Lancet Respir Med"},{"key":"2884_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, Howell P, Meressa D, Song W, et al. Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387:810\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2119430.","journal-title":"N Engl J Med"},{"key":"2884_CR26","volume-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022."},{"key":"2884_CR27","doi-asserted-by":"publisher","first-page":"106509","DOI":"10.1016\/j.jinf.2025.106509","volume":"91","author":"BD Daniel","year":"2025","unstructured":"Daniel BD, Shanmugam S, Mehta R, Bhalla M, Mariappan M, Ramraj B, et al. Long-term outcomes in drug-resistant tuberculosis with bedaquiline, pretomanid and varying doses of linezolid. J Infect. 2025;91:106509. https:\/\/doi.org\/10.1016\/j.jinf.2025.106509.","journal-title":"J Infect"},{"key":"2884_CR28","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1371\/journal.pmed.0050152","volume":"5","author":"CY Jeon","year":"2008","unstructured":"Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis. PLoS Med. 2008;5:e152.","journal-title":"PLoS Med"},{"key":"2884_CR29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1183\/09031936.00040910","volume":"36","author":"H Getahun","year":"2010","unstructured":"Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated TB. Eur Respir J. 2010;36:1242\u20139.","journal-title":"Eur Respir J"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02884-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02884-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:41:30Z","timestamp":1784126490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02884-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":29,"alternative-id":["2884"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02884-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee, King George\u2019s Medical University (Ref No: 126th ECMIIB-Ph.D\/P1). All procedures were performed in accordance withrelevant guidelines and regulations. Written informed consent was obtained from all participants prior to enrollment in the study. For participants unable to sign, consent was obtained by witnessed thumbprint.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}